Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
Gastrointestinal Health: Can be used to support the integrity of the gut lining and dogs with IBD, leaky gut or chronic digestive inflammation
Others benefit from repeated cycles for chronic or complex issues
People with more fat to lose see faster initial progress
BPC-157 is supplied for in vitro research use only
While not dangerous, they indicate significant vascular reactivity and suggest the nitric oxide system is responding robustly to the peptide